KPV Peptide Research & Evidence Review

Summary

KPV is the C-terminal tripeptide fragment (lysine–proline–valine) of alpha-melanocyte-stimulating hormone. It retains much of the parent hormone's anti-inflammatory signalling without its pigmentary effects. Research is concentrated in experimental colitis and dermatitis models; human trials are minimal.

Last reviewed 2026-09-01

What it is

KPV is a three–amino-acid peptide corresponding to residues 11–13 of alpha-MSH. It is one of the smallest fragments still showing measurable anti-inflammatory activity in models.

Work on alpha-MSH fragments began in the 1980s–1990s once it became clear that the hormone's anti-inflammatory and pigmentary activities could be separated across different regions of the sequence.

A fragment of an endogenous hormone; produced synthetically for research use.

Its size makes it cheap to synthesise and stable, and it can be taken up by intestinal epithelial cells through the PepT1 transporter, which drew interest for inflammatory bowel research.

How it works

In plain terms

KPV appears to quiet the master inflammatory switch inside cells, so damaged tissue produces fewer inflammatory signals.

Technical detail

The dominant reported mechanism is inhibition of NF-κB nuclear translocation and reduced downstream production of IL-6, IL-8 and TNF-α. In intestinal epithelium, uptake occurs via the PepT1 di/tripeptide transporter, giving a direct intracellular route. Melanocortin receptor engagement (MC1R) is reported for the parent hormone but KPV activity appears at least partly receptor-independent.

Pathways involved

NF-κB nuclear translocation inhibition
IL-6, IL-8 and TNF-α suppression
PepT1-mediated intestinal epithelial uptake
Melanocortin (MC1R) signalling, partial

Current research

Laboratory research

Epithelial and immune cell cultures show dose-dependent reduction in cytokine output after inflammatory challenge.

Animal research

DSS- and TNBS-induced colitis models in mice report reduced histological damage, lower myeloperoxidase activity and improved weight-loss curves. Topical models in dermatitis and wound infection report reduced inflammatory infiltrate.

Human research

Human evidence is limited to small dermatological observations and formulation studies. No adequately powered randomised trial in inflammatory bowel disease has been published.

Ongoing research

Registered activity is sparse; nanoparticle and oral-delivery formulation research is the most active area.

What is being investigated

Experimental colitis and intestinal inflammation
Topical dermatitis and skin inflammation
Cytokine suppression in epithelial cells
Antimicrobial activity against Candida and S. aureus in vitro
Oral and nanoparticle delivery to the gut

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

No adequately powered human trials in any indication
Suppressing inflammatory signalling has theoretical infection-risk implications that have not been studied in humans
Pharmacokinetics of an unmodified tripeptide in humans are poorly characterised
Product identity and purity vary; a tripeptide is easy to mislabel
Not an approved medicine in any jurisdiction

Evidence ratings

Laboratory studies

Moderate

Reproducible cytokine suppression in cell models.

Animal studies

Moderate

Consistent colitis-model findings across several groups.

Human studies

None

No adequately powered controlled trials published.

Long-term safety

None

No chronic exposure data.

References

[1]KPV peptide — indexed literature — PubMed, 1990–present
[2]KPV and experimental colitis — PubMed, 2008–present
[3]Alpha-MSH anti-inflammatory fragments — PubMed, 1995–present
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is KPV?+

The lysine–proline–valine tripeptide at the C-terminus of alpha-MSH, studied for anti-inflammatory activity.

How does KPV work?+

Principally by inhibiting NF-κB nuclear translocation, reducing IL-6, IL-8 and TNF-α production in epithelial and immune cells.

Is KPV related to melanotan?+

Both derive from alpha-MSH biology, but KPV lacks the pigmentary activity associated with melanocortin agonists such as melanotan peptides.

Is KPV FDA approved?+

No. It is not an approved drug in any major jurisdiction.

Why is KPV studied for gut inflammation?+

Intestinal cells take it up through the PepT1 transporter, so it can act inside the epithelium — attractive for inflammatory bowel models.

Does KPV have antimicrobial activity?+

In-vitro studies report activity against Candida albicans and Staphylococcus aureus, but this has not been demonstrated clinically.

What human research exists on KPV?+

Very little — small dermatological observations and formulation work. No powered randomised trials.

Is KPV the same as BPC-157?+

No. They are unrelated sequences with different proposed mechanisms; KPV targets inflammatory signalling, BPC-157 is studied mainly for angiogenesis.

Continue your research

Chronic inflammation explained

What Is BPC-157?

Peptide Research hub